Regeneron Director Christine A. Poon Exercises Options and Sells ~$7.59M in Stock

SEC Form 4 Transaction Analysis

Company: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
Reporting Person: Christine A. Poon
Relationship: Director
Filing Date: November 4, 2026
Transaction Date: November 2, 2026

Overview of Transactions

On November 2, 2026, Director Christine A. Poon exercised non-qualified stock options to acquire 7,830 shares of Common Stock at an exercise price of $376.69 per share. Concurrently, she sold all 7,830 acquired shares in multiple open-market tranches at weighted-average prices ranging between $966.74 and $971.31 per share.

• Total Shares Exercised: 7,830
• Total Exercise Cost: $2,949,482.70
• Total Shares Sold: 7,830
• Gross Proceeds from Sales: $7,587,957.78
• Net Realized Profit: $4,638,475.08
• Post-Transaction Direct Ownership: 5,219 shares of Common Stock

Breakdown of Sales Tranches

1. 218 shares at a weighted average price of $966.74 ($210,749.32)
2. 772 shares at a weighted average price of $967.38 ($746,817.36)
3. 2,499 shares at a weighted average price of $968.58 ($2,420,481.42)
4. 3,203 shares at a weighted average price of $969.50 ($3,105,308.50)
5. 937 shares at a weighted average price of $970.51 ($909,367.87)
6. 201 shares at a weighted average price of $971.31 ($195,233.31)

Significance

This transaction represents a routine "exercise and sell" event approaching option expiration (stated expiration date: January 3, 2027). While the dollar volume is notable at over $7.5M, the transaction resulted in zero net reduction of her prior base holdings of 5,219 shares, keeping her core position intact.